Bristol Myers Squibb (BMY) Enterprise Value (2009 - 2026)

Bristol Myers Squibb has disclosed Enterprise Value across 18 years of filings, most recently posting -$10.5 billion for Q1 2026.

• In Q1 2026, Enterprise Value rose 10.84% year-over-year to -$10.5 billion; the TTM figure through Mar 2026 stood at -$10.5 billion (up 10.84% YoY), while the FY2025 annual figure was -$10.6 billion, up 1.54% from the prior year.
• Enterprise Value improved to -$10.5 billion in Q1 2026, from -$10.6 billion in the prior quarter.
• Over the last five years, Enterprise Value for BMY reached as high as -$6.6 billion in Q2 2024 and fell as low as -$16.5 billion in Q3 2025.
• The 5-year median for Enterprise Value is -$10.5 billion (2026), against an average of -$10.7 billion.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 45.61% — and 2025, when it tumbled 105.32%.
• A 5-year view of Enterprise Value shows it stood at -$9.2 billion in 2022, then plunged by 32.94% to -$12.2 billion in 2023, then increased by 11.61% to -$10.8 billion in 2024, then advanced by 1.54% to -$10.6 billion in 2025, then grew by 1.77% to -$10.5 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$10.5 billion, -$10.6 billion, and -$16.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.